A 5 year (2005-2009) review of antimicrobial susceptibility of clinical Klebsiella pneumoniae isolates from pediatric patients in Jordan

Abstract

Aim of the Study: The present study was conducted to investigate antimicrobial susceptibility pattern of Klebsiella pneumoniae strains isolated from clinical specimens of Jordanian pediatric patients during a five year period from 2005-2009. A total of 1023 Klebsiella pneumoniae strains were isolated from clinical specimens and tested for their susceptibility to different antimicrobial drugs. Main findings: Overall, high susceptibility rate was recorded for ciprofloxacin (90.5%), followed by norfloxacin (84.8%), imipenem (69.9%), nalidixic acid (66.6%), and cefixime (63.9%). Low susceptibility rate was recorded for ampicillin (16.6%), followed by amoxicillin-clavulanic acid (22.5%), tobramycin (28.6%), amikacin (31.4%), cotrimoxazole (37.3%), and aztreonam (39.3%), Conclusion: most of β-lactam antibiotics as well as tobramycin, amikacin, cotrimoxazole, and aztreonam, should not be used in treating infections caused by pathogenic K. pneumoniae and other related bacteria in Jordan. However, quinolone compounds and imipenem seem to be effective in treatment of infections caused by pathogenic K. pneumoniae in children.

Keywords

• Antimicrobial resistant
• Klebsiella pneumoniae
• pediatric patients